I can't tell how soon after the stroke this was implemented so I don't know whether this is hyperacute or acute. Thats what your doctor is for.
http://www.digitaljournal.com/pr/1108379
Tarix Pharmaceuticals, a biopharmaceutical company focused on
developing novel, peptide-based therapies to treat a range of critical
medical conditions, today announced it has uncovered a new role for its
therapeutic peptides in stimulating revascularization following
ischemia.
In models of ischemic stroke and peripheral vascular disease,
treatment with either the Company's natural peptide, TXA127, or its
cyclic analog, PanCyte, resulted in increased blood flow and histologic
evidence of vasculogenesis (new blood vessel formation).
Rick Franklin, CEO of Tarix
Pharmaceuticals, stated, "We explored the therapeutic value of our
peptides following ischemia, due to their stimulatory effect on
endothelial progenitor cells, which are increased naturally during
ischemia and play an important role in vascular regeneration. We were
very pleased, and somewhat surprised, at the efficacy seen in these
models in which we saw a return to near-normal blood flow that
correlated with histologic evidence of new vessel formation. In
addition, in multiple models of ischemic stroke recovery, there was
significant improvement in a variety of clinically relevant neurologic
measurements."
Franklin continued, "Given this compelling data, we are now planning
to initiate clinical trials in ischemic stroke and peripheral vascular
disease in 2013."
The transient middle cerebral artery occlusion stroke model involved
fifteen animals per treatment group, and was randomized and blinded.
There were significant improvements in neurologic score, forelimb
placement, stepping test and body swing test, all of which are standard
measurements of functional response in stroke. Treatment was begun
twenty-four hours after the stroke, and positive results were detectable
within two weeks, and improvement continued throughout the seven-week
study. In addition, there was a substantial increase in cerebral blood
flow and histologic evidence of new blood vessel formation.
Separately, in a mouse model of unilateral hindlimb ischemia,
ischemic recovery was compared between TXA127 or PanCyte treatment
versus control animals. Blood flow in treated animals improved
significantly faster toward normal, with percent blood flow more than
double that of control animals by day 49 (~85% vs ~40%). Histologic
examination again showed a significant increase in the number of
functional blood vessels amongst treated animals compared to controls.
About Tarix PharmaceuticalsTarix Pharmaceuticals is a
biopharmaceutical company focused on developing novel, peptide-based
therapies to treat a range of critical medical conditions. Tarix'
proprietary technology platform consists of TXA127, a pharmaceutical
formulation of the naturally occurring peptide, Angiotensin (1-7), and
PanCyte, a cyclic analogue of TXA127 with an extended half-life. TXA127
and PanCyte have shown striking effects in models of ischemic stroke
and peripheral vascular disease through improvement in endothelial
progenitor cell number and function. The peptides have also been
effective in models of diabetes. Tarix intends to initiate clinical
trials in these indications during 2013, adding to its clinical pipeline
that includes multiple programs in hematopoiesis.
No comments:
Post a Comment